-
Mashup Score: 3
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
China’s NMPA has approved the oral, next-generation ROS1 TKI taletrectinib adipate for adult patients with locally advanced or metastatic ROS1-positive NSCLC who have been previously treated with ROS1 TKIs. #LCSM #oncology #MedTwitter https://t.co/qLgUOPcDtu
-
-
Mashup Score: 1
The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC @EMA_News #lcsm #oncology #MedTwitter https://t.co/hLd4q8lx5W
-
-
Mashup Score: 1
The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC @EMA_News #lcsm #oncology #MedTwitter https://t.co/hLd4q8lx5W
-
-
Mashup Score: 1
The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC @EMA_News #lcsm #oncology #MedTwitter https://t.co/hLd4q8lx5W
-
-
Mashup Score: 1Revisit Every OncLive On Air Episode From October 2024 - 2 month(s) ago
In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
In case you missed any, read a recap of every episode of OncLive On Air® that aired in October 2024. #lcsm #oncology #MedTwitter Read here: https://t.co/3ryvCjHkKZ
-
-
Mashup Score: 4
The HERTHENA-Lung02 trial met its primary end point of improved PFS with patritumab deruxtecan in pretreated EGFR-mutated non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC #lcsm #oncology #MedTwitter https://t.co/K1jzdlggQN
-
-
Mashup Score: 3
GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer @US_FDA #lcsm #oncology #MedTwitter https://t.co/8R4PDPPlCv
-
-
Mashup Score: 3
GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer @US_FDA #lcsm #oncology #MedTwitter https://t.co/8R4PDPPlCv
-
-
Mashup Score: 3
GSK5764227 has received breakthrough therapy designation from the FDA for use in select patients with extensive-stage small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
FDA Grants BTD to GSK5764227 for Extensive-Stage Small Cell Lung Cancer @US_FDA #lcsm #oncology #MedTwitter https://t.co/8R4PDPPlCv
-
China’s NMPA has approved the oral, next-generation ROS1 TKI taletrectinib adipate for adult patients with locally advanced or metastatic ROS1-positive NSCLC who have been previously treated with ROS1 TKIs. #LCSM #oncology #MedTwitter https://t.co/qLgUOPcDtu